General research interest:
Many undesired side-effects or therapeutic failure of drugs are the results of differences or alterations of drug metabolism. Our team deals with interindividual differences in drug metabolism and elimination for more than 20 years. Our research activity focuses on the function and regulation of cytochrome P450 (CYP) enzymes, primarily involved in the metabolism of xenobiotics.
Biochemical, molecular biological and mass spectrometric approaches are applied for studying I) metabolism and pharmacokinetic interactions of drugs and drug-candidates under development, II) factors influencing the expression and function of CYP enzymes (hormonal status, disease, drug therapy), III) moreover, diagnostic approaches for patients’ drug metabolism capacity provide tools for personalized medication.
Main research projects:
1. Strategy for personalized medication adjusted to patients’ drug-metabolizing capacity
CYPtestTM, the multi-step diagnostic system for the estimation of patients’ drug-metabolizing capacity, identifies defective CYP alleles by DNA analysis (CYP-genotyping) and provides information about the current expression of key drug-metabolizing CYP enzymes by CYP-phenotyping. The validation and clinical introduction of CYPtestTM has been started for patients who are on multi-drug therapy or for those who particularly benefit from tailored medication by increasing drug efficacy and by significantly decreasing the risk of the toxicity. The main focus is on the patients’ reduced or even extensive drug-metabolizing capacity (transplant recipients, psychiatric and neurologic patients as well as in patients suffering from liver dysfunction and cardiovascular diseases) which may potentially lead to therapeutic failure and severe adverse drug reactions. By recognizing poor or extensive drug metabolism, tailored medication adjusted to the patients’ drug-metabolizing capacity (by the optimization of the most appropriate drug and dosage) can minimize harmful side effects and ensure a more rational drug therapy and a more successful outcome.
2. Possibilities of personalized therapy
Systematic evaluation of the role of drug-metabolizing CYP enzymes in the metabolism of the antipsychotics, mood-stabilizers and antiepileptics frequently applied in treatment of psychiatric and neurologic patients as well as of immunosuppressant drugs, the main components of transplant patients’ therapy. The contribution of CYP polymorphisms (genetic and non-genetic variations) to inter-individual differences in the efficacy and toxicity of these drugs are estimated.
2.1. CYP3A-status, taking both CYP3A4 expression and CYP3A5 genotype into account, influences recipients’ calcineurin inhibitor therapy after transplantation. In liver transplant patients, CYP3A-status of the donor liver contributes to the recipient’s blood concentrations of ciclosporin and tacrolimus. It has been reported that patients transplanted with liver grafts from low or high expressers or with grafts carrying functional CYP3A5*1 allele required substantial modification of the initial calcineurin inhibitor dose. Donor livers’ CYP3A-status can better identify the risk of calcineurin inhibitor over- or underexposure, and may contribute to the avoidance of misdosing-induced graft injury in the early postoperative period.
2.2. The clinical consequences of decreased CYP2C9 function were investigated in epileptic children. It has been established that valproic acid, one of the first choices of antiepileptic drugs, is metabolized primarily by CYP2C9 in pediatric patients. Identification of loss-of-function mutations in CYP2C9 may lead to false prediction of a patient’s valproate metabolizing capacity, since CYP2C9 expression highly influences blood concentrations of valproate.
Patients’ CYP2C9-status guided dosing strategy for achieving the optimal blood concentration has been suggested.
CYP2C9-guided (CYP2C9 genotype and CYP2C9 expression) treatment significantly reduced the ratio of patients out of the range of target valproate blood concentrations, the ratio of patients with abnormal serum alkaline phosphatase levels and the incidence of serious side effects, notably hyperammonemia.
2.3. The incidence of adverse reactions in the anticonvulsant clonazepam therapy is highly attributed to the inter-individual variability in clonazepam metabolism by CYP3A and NAT2 (N-acetyl transferase 2) enzymes. The patients’ CYP3A4 expression was found to be the major determinant of clonazepam plasma concentrations; whereas CYP3A5 genotype and NAT2 acetylator phenotype did not influence the steady state levels of clonazepam.
However, the normal CYP3A4 expression and slow NAT2 acetylator phenotype evoking high plasma concentration ratio of 7-amino-clonazepam and clonazepam, may account for low efficacy or withdrawal symptoms of clonazepam. Prospective assaying of CYP3A4 expression and NAT2 acetylator phenotype can better identify the patients with higher risk of adverse reactions and can facilitate the improvement of personalized clonazepam therapy and withdrawal regimen.
2.4. The atypical antipsychotic clozapine is effective in treatment-resistant schizophrenia; however, the success or failure of clozapine therapy is substantially affected by the variables that impact the clozapine blood concentration. CYP3A4 expression was found to be the major determinant of normalized clozapine concentration, particularly in patients expressing CYP1A2 at relatively low level. The functional CYP3A5*1 allele seemed to influence clozapine concentrations in those patients who expressed CYP3A4 at low levels. Strong association was observed between the metabolite/clozapine ratios and CYP3A4 mRNA levels, which confirmed the primary role of CYP3A4 in clozapine metabolism.
3. Modelling of cross-talk between sterol homeostasis and drug metabolism
The natural changes in hormonal status, or therapeutic steroids can cause substantial alteration in CYP gene expression and in CYP enzyme protein levels. The cross-talk between drug-metabolizing CYP enzymes and steroids such as dehydroepiandrosterone (DHEA), dexamethasone and cholesterol is investigated.
4. The effect of portal vein ligation on drug-metabolizing function of the liver
The alterations as the consequence of atrophy-hypertrophy (regeneration) resulted by liver-surgical interventions (portal vein-occlusion, resection) are investigated in rat-model. These surgical maneuvers can lead to the modification of hepatic drug metabolism, particularly in early postoperative period.
- Cell-culture laboratory equipped with CO2 incubator, Esco Class II Biological Safety Cabinet, microscope
- HPLC UV-VIS, radiodetector
- NanoDrop 1000 Spectrophotometer
- Real-time PCR and end-point PCR systems (BioRad)
- Western blot systems
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia – The cross-talk between cholesterol homeostasis and drug- metabolism
- Palacky University, Olomouc, Czech Republic – The effect of the steroid type compounds (dexamethasone, dehydroepiandrosterone) on drug-metabolizing cytochrome P450 enzymes
- INSERM (Institut National de la Santé et de la Recherche Médicale) U632, Montpellier, France – The role of nuclear receptors in the regulation of cytochrome P450 enzymes
- Department of Transplantation and Surgery, Semmelweis University, Budapest – Drug metabolism in transplant patients; Prevention of toxicity resulted from ciclosporin metabolism
- Heart and Vascular Center, Semmelweis University, Budapest – Drug metabolism in transplant patients; Prevention of toxicity resulted from immunosuppressant metabolism
- Department of Psychiatry and Psychotherapy, Semmelweis University, – Possibilities of personalized antipsychotic therapy
- Madarász Hospital, Heim Pál Children’s Hospital , Budapest – Personalized antiepileptic therapy
- 2ndDepartment of Pediatrics, Semmelweis University – CYP copy number variations in tumorous tissues
- St László Hospital, Budapest – Personalized therapy of bone-marrow transplant patients
- 1st Department of Surgery, Semmelweis University, Budapest – The effect of portal vein ligation on drug-metabolizing function of the liver
- Semmelweis University, Budapest
- Eötvös Loránd University, Budapest
- Budapest University of Technology and Economics, Budapest
Kiss Á, Tóth K, Juhász C, Temesvári M, Paulik J, Hirka G, Monostory K: Is CYP2D6 phenotype predictable from CYP2D6 genotype? Microchemical Journal 136: 209-214, 2018
Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K: Potential role of patients’ CYP3A-status in clozapine pharmacokinetics. International Journal of Neuropsychopharmacology 20: 529-537, 2017
Tóth K, Csukly G, Sirok D, Belic A, Háfra E, Kiss Á, Déri M, Menus Á, Bitter I, Monostory K: Optimization of clonazepam therapy adjusted to patient’s CYP3A-status and NAT2 genotype. International Journal of Neuropsychopharmacology 19: 1-9, 2016
Bűdi T, Tóth K, Nagy A, Szever Z, Kiss Á, Temesvári M, Háfra E, Garami M, Tapodi A, Monostory K: Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia., 56(6):849-55, 2015
Monostory K, Tóth K, Kiss Á, Háfra E, Csikány N, Paulik J, Sárváry E, Kóbori L: Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. Br J Clin Pharmacol, 80(6):1429-37,2015
Tóth K, Bűdi T, Kiss Á, Temesvári M, Háfra E, Nagy A, Szever Z, Monostory K: Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy. Personalized Medicine, 12(3): 199-207,2015
Belic A, Tóth K, Vrzal R, Temesvári M, Porrogi P, Orbán E, Rozman D, Dvorak Z, Monostory K: Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor. Chemico-Biological Interactions, 203: 597-603, 2013
Temesvári M, Kóbori L, Paulik J, Sárváry E, Belic A, Monostory K: Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. Journal of Pharmacology and Experimental Therapeutics 341: 294-305, 2012
Temesvári M, Paulik J, Kóbori L, Monostory K: High-resolution melting curve analysis to establish CYP2C19*2 single nucleotide polymorphism: comparison with hydrolysis SNP analysis. Molecular and Cellular Probes 25: 130-133, 2011
Monostory K, Dvorak Z: Steroid regulation of drug-metabolizing cytochromes P450. Current Drug Metabolism 12: 154-172, 2011
Rezen T, Rozman D, Pascussi J-M, Monostory K: Interplay between cholesterol and drug metabolism. Biochim Biophys Acta – Proteins and Proteomics 1814: 146-160, 2011
Rozman D, Monostory K: Perspectives of the non-statin hypolipidemic agents. Pharmacology and Therapeutics. 127: 19-40, 2010
Belic A, Temesvári M, Kőhalmy K, Vrzal R, Dvorak Z, Rozman D, Monostory K: Investigation of the CYP2C9 induction profile in human hepatocytes by combining experimental and modelling approaches. Current Drug Metabolism 10: 457-461, 2009
Monostory K, Pascussi J-M, Kóbori L, Dvorak Z: Hormonal regulation of CYP1A expression. Drug Metabolism Reviews 41: 547-572, 2009
Monostory K, Pascussi J-M, Szabó P, Temesvári M, Kőhalmy K, Acimovic J, Kocjan D, Kuzman D, Wilzewski B, Bernhardt R, Kóbori L, Rozman D: Drug-interaction potential of 2-((3,4-(dichlorophenethyl(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel non-statin type cholesterol lowering agent. Drug Metabolism and Disposition 37: 375-385, 2009
Kóbori L, Kőhalmy K, Porrogi P, Sárváry E, Gerlei Zs, Fazakas J, Nagy P, Járay J, Monostory K: Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism. British Journal of Clinical Pharmacology 65: 428-436, 2008
Kőhalmy K, Tamási V, Kóbori L, Sárváry E, Pascussi J-M, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K: Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metabolism and Disposition 35: 1495-1501, 2007
Monostory K, Kőhalmy K, Prough, RA, Kóbori L, Vereczkey L: The effect of synthetic glucocorticoid, dexamethasone on CYP1A1 inducibility in adult rat and human hepatocytes. FEBS Letters 579: 229-235, 2005
Monostory K, Hazai E, Vereczkey L: Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chemico-Biological Interactions 147: 331-340, 2004
Szűcs G, Tamási V, Laczay P, Monostory K: Biochemical background of toxic interaction between tiamulin and monensin. Chemico-Biological Interactions 147: 151-161, 2004
Tamási V, Hazai E, Porsmyr-Palmertz M, Ingelman-Sundberg M, Vereczkey L, Monostory K: GYKI-47261, a new AMPA antagonist is a CYP2E1 inducer. Drug Metabolism and Disposition 31:1310-1314, 2003
Tamási V, Vereczkey L, Falus A, Monostory K: Some aspects of interindividual variations in the metabolism of xenobiotics. Inflammation Research 52:322-333, 2003
Hazai E, Vereczkey L, Monostory K: Reduction of toxic metabolite formation of acetaminophen. Biochemical Biophysical Research Communications 291: 1089-1094, 2002
Tamási V, Kiss Á, Dobozy O, Falus A, Vereczkey L, Monostory K: The effect of dexamethasone on P450 activities in regenerating liver. Biochemical Biophysical Research Communications 286: 239-242, 2001
Monostory K, Vereczkey L, Lévai F, Szatmári I: Iprifalvone as an inhibitor of human cytochrome P450 enzymes. British Journal of Pharmacology 123: 605-610, 1998
Monostory K, Jemnitz K, Vereczkey L, Czira G: Species differences in metabolism of panomifene, an analogue to tamoxifen. Drug Metabolism and Disposition 25: 1370-1378, 1997
Monostory K, Vereczkey L: The effect of phenobarbital and dexamethasone coadministration on the activity of rat liver P450 system. Biochemical Biophysical Research Commununications 203: 351-358, 1994
|124||http://www.ttk.mta.hu/telefonkonyv/deri-mate-tamas||Déri Máté Tamás||Máté Tamás Déri||+36 1 3826 643||http://www.ttk.mta.hu/ei||Enzimológiai Intézet||http://www.ttk.mta.hu/ei/en||Institute of Enzymology||http://www.ttk.mta.hu/ei/metabolikus-gyogyszer-kolcsonhatasok-kutatocsoport||Metabolikus Gyógyszer-kölcsönhatások Kutatócsoport||Metabolic drug-interactions Research Group||É2.10|
|187||http://www.ttk.mta.hu/telefonkonyv/gabri-evelyn-erzsebet||Gabri Evelyn Erzsébet||Evelyn Erzsébet Gabri||+36 1 3826 648, +36 1 3826 643||http://www.ttk.mta.hu/ei||Enzimológiai Intézet||http://www.ttk.mta.hu/ei/en||Institute of Enzymology||http://www.ttk.mta.hu/ei/metabolikus-gyogyszer-kolcsonhatasok-kutatocsoport||Metabolikus Gyógyszer-kölcsönhatások Kutatócsoport||Metabolic drug-interactions Research Group||É2.10|
|322||http://www.ttk.mta.hu/telefonkonyv/kiss-adam-ferenc||Kiss Ádám Ferenc||Ádám Ferenc Kiss||tudományos segédmunkatárs||+36 1 3826 641,+36 1 3826 643,+36 1 3826 648, +36 1 3826 747||http://www.ttk.mta.hu/ei||Enzimológiai Intézet||http://www.ttk.mta.hu/ei/en||Institute of Enzymology||http://www.ttk.mta.hu/ei/metabolikus-gyogyszer-kolcsonhatasok-kutatocsoport||Metabolikus Gyógyszer-kölcsönhatások Kutatócsoport||Metabolic drug-interactions Research Group||É2.10, É3.11A ; É2.13|
|428||http://www.ttk.mta.hu/telefonkonyv/mango-katalin||Mangó Katalin||Katalin Mangó||+36 1 382 6643,+36 1 382 6648,+36 1 382 6748||http://www.ttk.mta.hu/ei||Enzimológiai Intézet||http://www.ttk.mta.hu/ei/en||Institute of Enzymology||Metabolic drug-interactions Research Group||É2.10, É3.11A ; É2.13|
|468||http://www.ttk.mta.hu/telefonkonyv/monostory-katalin||Monostory Katalin||Katalin Monostory||kutatócsoport-vezető||+36 1 382 6747||http://www.ttk.mta.hu/ei||Enzimológiai Intézet||http://www.ttk.mta.hu/ei/en||Institute of Enzymology||Metabolic drug-interactions Research Group||É3.11A|
|772||http://www.ttk.mta.hu/telefonkonyv/toth-katalin||Tóth Katalin||Katalin Tóth||tudományos segédmunkatárs||+36 1 3826 643, +36 1 3826 648||http://www.ttk.mta.hu/ei||Enzimológiai Intézet||http://www.ttk.mta.hu/ei/en||Institute of Enzymology||Metabolic drug-interactions Research Group||É2.10, É3.11A ,É2.13|